Boosting Trial Success through Blinded Data Analytics: What Can We Learn from CNS

February 25, 2020

Research scientists know that data alone do not lie - but data can mislead. That's especially true in clinical trials that rely on subjective endpoints to assess drug efficacy.

Psychiatry studies, for example, which often center around the clinician's assessment of disease progression or severity, have modest success rates. Just 24% of Phase II and 56% of Phase III psychiatric studies demonstrate a statistically significant drug-placebo separation. But is it true that so many medications, having moved so far through the development pathway, do not work, or is something else at play?

No Previous Flipbooks

Next Flipbook
The Difference a Step Makes - International Clinical Trials
The Difference a Step Makes - International Clinical Trials

Signant Health explains why a purpose-built clinical supply chain platform is a must-have for 2020 and beyond.